Cell free protein expression market

Cell-Free Protein Expression Market, by Product Type (E. coli Cell-free Protein Expression System, Rabbit Reticulocytes Cell-free Protein Expression System, Wheat Germ Cell-free Protein Expression System, Insect Cells Cell-free Protein Expression System, Mammalian Cell-free Protein Expression System, Labelling Tags, and Others {Vectors, yeast cell extracts, among others}), by Expression Mode (Continuous flow Expression, and Batch Expression), by Application (Enzyme Engineering, Protein Labeling, Protein-Protein interaction, Protein Purification, and Others {High Throughput Production, among others}), by End User (Biotechnological Companies, Pharmaceutical Companies, Contract Research Organizations, and Academic/ Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Sep 2022
CMI1082
182 Pages
Excel & Pdf
Biotechnology

Summary

Cell-free protein expression is an essential tool for molecular biologists in basic as well as applied sciences. Cell-free protein expression is increasingly being adopted by researchers in high-throughput functional proteomics and genomics, as it has significant advantages over protein expression in living cells. Cell-free protein expression is essential for enzyme engineering using display technologies and the generation of protein arrays, such as nucleic acid programmable protein array (NAPPA). Cell-free protein expression requires a DNA template (which can be either a plasmid or a polymerase chain reaction product) encoding the target protein, and a solution containing all the necessary components such as translation factors, transcription factors, enzymes, and others to carry out transcription and translation. This solution is a cell-free extract, as it consists only the organelle and cytosolic material while the cell membrane has been removed. When the genetic material and the cell-free extract are combined, expression of the target protein can start.

Global cell-free protein expression market is estimated to be valued at US$ 280.2 million in 2022 and is expected to exhibit a CAGR of 6.4% over the forecast period (2022-2030).

Figure 1. Global Cell-Free Protein Expression Market Share (%), By Region, 2022

Rising cases of chronic diseases such as cancer, diabetes, cardiovascular disease, and others creates a demand for personalized medicine which can be achieved using cell-free protein expression. This is expected to drive growth of the global cell-free protein expression market over the forecast period.

For instance, according to data published in the International Diabetes Federation (IDF) Diabetes Atlas Tenth edition 2021, in December 2021, it is estimated that around 537 million adults (20-79 years) were suffering from diabetes across the globe in 2021. The same source also estimates that the total number of people suffering from diabetes will rise to around 643 million by 2030 and 783 million by 2045, globally.

Cell-free Protein Expression Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 280.2 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	6.4 %	2030 Value Projection:	US$ 459.9 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: E. coli Cell-free Protein Expression System, Rabbit Reticulocytes Cell-free Protein Expression System, Wheat Germ Cell-free Protein Expression System, Insect Cells Cell-free Protein Expression System, Mammalian Cell-free Protein Expression System, Labelling Tags, Others (Vectors, yeast cell extracts, among others) By Expression Mode: Continuous flow Expression, Batch Expression By Application: Enzyme Engineering, Protein Labeling, Protein-Protein interaction, Protein Purification, Others (High Throughput Production, among others) By End User: Biotechnological Companies, Pharmaceutical Companies, Contract Research Organizations, Academic/ Research Institutes
Companies covered:	Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, Bioneer Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Daicel Arbor Biosciences Daicel Arbor Biosciences, Profacgen, Creative Biolabs, biotechrabbit, Roche Molecular Systems, Inc., Cusabio Technology LLC, and LenioBio
Growth Drivers:	Increasing incidence of chronic diseases such as diabetes, cancer, etc. and rising demand of personalized medicines for its treatment Rapid research and development activities by market players
Restraints & Challenges:	High cost of protein expression systems Lack of effective systems for post-translational modifications

Figure 2. Global Cell-Free Protein Expression Market Value (US$ Mn), By Product Type, 2022

Increasing marketing strategies by key players to increase awareness about advancements in their cell-free protein expression systems is expected to drive market growth over the forecast period.

For instance, on June 1, 2022, Codex DNA, Inc., a U.S.-based synthetic biology company announced that it would be presenting its BioXp system and RapidAMP technology for antibody and protein engineering workflows at Antibody Engineering and Therapeutics Europe Conference held from June 7 to 9, 2022. BioXp system provides hands-free, end-to-end automation of DNA assembly, cloning, amplification, and mRNA synthesis in a single run.

Global Cell-Free Protein Expression Market – Impact of Coronavirus (Covid-19) Pandemic

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 523 million population leading to more than 6.3 million deaths as of June 5, 2022. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. However, the COVID-19 pandemic had a positive impact on the overall growth of the cell-free protein expression market, owing to use of cell-free protein expression systems to develop new tools, vaccines, and treatments for COVID-19 patients.

For instance, in November 2021, researchers from the North-western University, U.S., developed a cell-free, high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus (SARS-CoV-2) antibodies generated in response to COVID-19 vaccines. These antibodies have high efficacy in preventing SARS-CoV-2 infection and symptomatic disease. In addition to therapeutic usage, these antibodies are widely used in immunoassays for the rapid detection of viral antigens.

Global Cell-Free Protein Expression Market - Restraint

High cost of protein expression systems and lack of effective systems for post-translational modifications are the factors that are expected to hinder growth of the global cell-free protein expression market over the forecast period.

Cell-free protein expression systems are not feasible for large-scale protein expression, as it can turn into a capital-intensive process due to expensive reagents such as phosphate chemicals in nucleotide form and secondary energy sources.

Moreover, the addition of energy and substrate sources in the process can have a negative impact on the cell-free protein expression systems due to short reaction scales which lead to the limited ability of resultant protein foldings during protein expression.

Key Players

Major players operating in the global cell-free protein expression market include Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, Bioneer Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Daicel Arbor Biosciences Daicel Arbor Biosciences, Profacgen, Creative Biolabs, biotechrabbit, Roche Molecular Systems, Inc., Cusabio Technology LLC, and LenioBio

Table of Content

Table of Contents

*Browse 58 market data tables and 43 figures on "Global Cell-Free Protein Expression Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global cell-free protein expression market during the forecast period (2022-2030)?

Global cell-free protein expression market size is estimated to be valued at US$ 280.2 million in 2022 and is expected to exhibit a CAGR of 6.4% between 2022 and 2030.

What are the major factors driving the market growth?

Rising number of cases of chronic diseases such as cancer, diabetes, etc. as well as rapid research and development activities for the development of novel cell-free protein expression products are expected to drive the market growth over the forecast period.

Which is the leading product type segment in the market?

E. coli Cell-free Protein Expression System segment is expected to hold the major market share in the market.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering growth of the market?

Major factors hampering growth of the market include high cost of protein expression systems and lack of effective systems for post-translational modifications.

Which are the major players operating in the market?

Major players operating in the market include Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, Bioneer Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Daicel Arbor Biosciences Daicel Arbor Biosciences, Profacgen, Creative Biolabs, biotechrabbit, Roche Molecular Systems, Inc., Cusabio Technology LLC, and LenioBio.